Pembrolizumab – March 2022

Pembrolizumab (Oesophageal carcinoma or HER-2-neg gastroesophageal junction adenocarcinoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®

Brand names:
- Keytruda®
Pharmaceutical Company:
- Merck Sharp & Dohme (Australia) Pty Ltd
Condition/Indication: Oesophageal carcinoma or HER-2-negative gastroesophageal junction adenocarcinoma
Meeting Date: March 2022
Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 839KB)
Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 339KB)

Related Public Summary Documents

Pembrolizumab – November 2021

Last updated

15 July 2022